Transforming growth factor-beta1 (TGF-beta 1) plays a crucial role in tumor progression. It can inhibit early cancer stages but promotes tumor growth and development at the late stages of tumorigenesis. TGF-beta 1 has a potent immunosuppressive function within the tumor microenvironment that largely contributes to tumor cells' immune escape and reduction in cancer immunotherapy responses. Likewise, myeloid-derived suppressor cells (MDSCs) have been postulated as leading tumor promoters and a hallmark of cancer immune evasion mechanisms. This review attempts to analyze the prominent roles of both TGF-beta 1 and MDSCs and their interplay in cancer immunity. Furthermore, therapies against either TGF-beta 1 or MDSCs, and their potential synergistic combination with immunotherapies are discussed. Simultaneous TGF-beta 1 and MDSCs inhibition suggest a potential improvement in immunotherapy or subverted tumor immune resistance.
TY - JOUR
AU - Mojsilović, Slavko
AU - Mojsilović, Sonja
AU - Bjelica, Sunčica
AU - Santibanez, Juan
PY - 2022
UR - http://rimi.imi.bg.ac.rs/handle/123456789/1180
AB - Transforming growth factor-beta1 (TGF-beta 1) plays a crucial role in tumor progression. It can inhibit early cancer stages but promotes tumor growth and development at the late stages of tumorigenesis. TGF-beta 1 has a potent immunosuppressive function within the tumor microenvironment that largely contributes to tumor cells' immune escape and reduction in cancer immunotherapy responses. Likewise, myeloid-derived suppressor cells (MDSCs) have been postulated as leading tumor promoters and a hallmark of cancer immune evasion mechanisms. This review attempts to analyze the prominent roles of both TGF-beta 1 and MDSCs and their interplay in cancer immunity. Furthermore, therapies against either TGF-beta 1 or MDSCs, and their potential synergistic combination with immunotherapies are discussed. Simultaneous TGF-beta 1 and MDSCs inhibition suggest a potential improvement in immunotherapy or subverted tumor immune resistance.
PB - Wiley
T2 - Developmental Dinamics
T1 - Transforming growth factor-beta1 and myeloid-derived suppressor cells: A cancerous partnership
EP - 124
IS - 1
SP - 105
DO - 10.1002/dvdy.339
ER -
@article{
author = "Mojsilović, Slavko and Mojsilović, Sonja and Bjelica, Sunčica and Santibanez, Juan",
year = "2022",
abstract = "Transforming growth factor-beta1 (TGF-beta 1) plays a crucial role in tumor progression. It can inhibit early cancer stages but promotes tumor growth and development at the late stages of tumorigenesis. TGF-beta 1 has a potent immunosuppressive function within the tumor microenvironment that largely contributes to tumor cells' immune escape and reduction in cancer immunotherapy responses. Likewise, myeloid-derived suppressor cells (MDSCs) have been postulated as leading tumor promoters and a hallmark of cancer immune evasion mechanisms. This review attempts to analyze the prominent roles of both TGF-beta 1 and MDSCs and their interplay in cancer immunity. Furthermore, therapies against either TGF-beta 1 or MDSCs, and their potential synergistic combination with immunotherapies are discussed. Simultaneous TGF-beta 1 and MDSCs inhibition suggest a potential improvement in immunotherapy or subverted tumor immune resistance.",
publisher = "Wiley",
journal = "Developmental Dinamics",
title = "Transforming growth factor-beta1 and myeloid-derived suppressor cells: A cancerous partnership",
pages = "124-105",
number = "1",
doi = "10.1002/dvdy.339"
}
Mojsilović, S., Mojsilović, S., Bjelica, S.,& Santibanez, J.. (2022). Transforming growth factor-beta1 and myeloid-derived suppressor cells: A cancerous partnership. in Developmental Dinamics
Wiley.(1), 105-124.
https://doi.org/10.1002/dvdy.339
Mojsilović S, Mojsilović S, Bjelica S, Santibanez J. Transforming growth factor-beta1 and myeloid-derived suppressor cells: A cancerous partnership. in Developmental Dinamics. 2022;(1):105-124.
doi:10.1002/dvdy.339 .
Mojsilović, Slavko, Mojsilović, Sonja, Bjelica, Sunčica, Santibanez, Juan, "Transforming growth factor-beta1 and myeloid-derived suppressor cells: A cancerous partnership" in Developmental Dinamics, no. 1 (2022):105-124,
https://doi.org/10.1002/dvdy.339 . .
